A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

by | Jun 9, 2025 | Clinical Trials | 0 comments

​ Conditions: Colon Cancer; Rectal Cancer; Colorectal Cancer; Colorectal Cancer (CRC)

Interventions: Drug: fruquintinib; Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)

Sponsors: SCRI Development Innovations, LLC; Takeda Development Center Americas, Inc.

Not yet recruiting Conditions: Colon Cancer; Rectal Cancer; Colorectal Cancer; Colorectal Cancer (CRC)
Interventions: Drug: fruquintinib; Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Sponsors: SCRI Development Innovations, LLC; Takeda Development Center Americas, Inc.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *